| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[25] Tranexamic acid, IV: CRASH-2 trial collaborators: Shakur H et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376:23-32. https://www.ncbi.nlm.nih.gov/pubmed/20554319
Tranexamic acid: Roberts I et al. The importance of early treatment with tranexamic acid in bleedingtrauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377:1096-1101.
Tranexamic acid: Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015 May 9;(5):CD004896. https://www.ncbi.nlm.nih.gov/pubmed/25956410